NCT05521022 - Study of AT-02 in Healthy Volunteers and Subjects With Systemic Amyloidosis | Biotech Hunter

Enrollment

100

Participants

Timeline

Start Date

September 1, 2022

Primary Completion Date

March 1, 2025

Study Completion Date

March 1, 2025

Conditions

Amyloidosis; Systemic

Interventions

DRUG

AT-02

AT-02 via IV infusion

OTHER

AT-02 (Placebo)

Normal saline solution via IV infusion

Trial Locations (11)

3128

RECRUITING

Box Hill Hospital, Box Hill

4006

RECRUITING

Q-Pharm Pty Ltd, Herston

4102

RECRUITING

Princess Alexandra Hospital, Woolloongabba

5042

RECRUITING

Flinders Medical Centre, Bedford Park

6000

RECRUITING

Royal Perth Hospital, Perth

19104

RECRUITING

Penn Presbyterian Medical Center, Philadelphia

21287

RECRUITING

Johns Hopkins, Baltimore

44195

RECRUITING

Cleveland Clinic, Cleveland

64111

RECRUITING

St. Luke's Hospital of Kansas City, Kansas City

66211

RECRUITING

Midwest Heart and Vascular, Overland Park

97239

RECRUITING

OHSU (Oregon Health & Science University), Portland